Value-based pricing: Examples of healthcare system reforms from the UK and US and implications for industry

Pharmaceutical Medicine

Volumn 26, Issue 4, 2012, Pages 217-222

  Miller, David W ^a  

^a Medical Research   (United Kingdom)

Author keywords

Cost effectiveness; Decision making; Pharmaceutical industry; Postmarketing surveillance; Quality of life; Research and development.

Indexed keywords

ANTINEOPLASTIC AGENT; NEW DRUG;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG INDUSTRY; DRUG RESEARCH; FUNDING; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH INSURANCE; HUMAN; MEDICAL RESEARCH; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; UNITED KINGDOM; UNITED STATES;

EID: 84864368549     PISSN: 11782595     EISSN: 11791993     Source Type: Journal    
DOI: 10.1007/bf03262478     Document Type: Article

References (32)

1. Accounting for the cost of health care in the United States, McKinsey Global Institute, January 2007 [online]. Available from URL: Http://www.mckinsey. com/mgi [Accessed 2011 Oct 19]
2. Centers for Medicare and Medicaid Services, National Health Expenditure Data [online]. Available from URL: Https://www.cms.gov/NationalHealth ExpendData/25-NHE-Fact-Sheet.asp [Accessed 2011 Oct 18]
3. International, B. M. Pharmaceuticals & Healthcare Report United Kingdom Healthcare. Business Monitor International, 2010
4. Sorenson C. Use of comparative effectiveness research in drug coverage and pricing decisions: A six-country comparison. New York: The Commonwealth Fund, 2010
5. Hughes DA. Value based pricing: Incentive for innovation or zero net benefit? Pharmacoeconomics 2011; 29 (9): 731-5
6. House of Commons. Health and social care bill: Ill 132 of 2010-11, presented to the House of Commons 31 January 2011 [online]. Available from URL: Www.parliament.uk/briefing-papers/RP11-11.pdf [Accessed 2012 May 24]
7. Office of Fair Trading. The pharmaceutical price regulation scheme. 2007 [online]. Available from URL: Http://www.oft.gov.uk/OFTwork/marketswork/ pprs [Accessed 2012 May 24]
8. Rawlins M, Barnett D, Stevens A. Pharmacoeconomics: NICE's approach to decision-making. Br J Clin Pharmacol 2010; 70 (3): 346-9
9. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd ed. New York: Oxford University Press, 2005
10. Claxton K. OFT,VBP: QED? Health Economics 2007; 16: 545-58
11. Claxton K, Sculpher M, Carroll S. Value-based pricing for pharmaceuticals: Its role, specification and prospects in a newly devolved NHS. Centre for Health Economics, York: University of York: 2011
12. Hughes DA, Ferner RE. New drugs for old: Disinvestment and NICE. BMJ 2010; 340: C572
13. Camps WalshG, Aivas I, Barratt H. ImprovingUKpatient outcomes: How can value-based pricing improve access and adoption of new treatments? September 2009. Interim report 2020health.org [online]. Available from URL: Www.2020health.org/dms/2020health/.../2020vpcdoc-sep09.pdf [Accessed 2012 May 24]
14. Kanavos P, Manning J, Taylor D, et al. Implementing value-based pricing for pharmaceuticals in theUK. Final report March 2010, 2020health.org [online]. Available from URL: Www.2020health.org/dms/2020health/.../reports/2020 vpblow26-04.pdf [Accessed 2012 May 24]
15. Towse A. Value based pricing, research and development, and patient access schemes: Will the United Kingdom get it right or wrong? Br J Clin Pharmacol 2010; 70 (3): 360-6
16. NICE Annual Conference. 2011 May 10-11; Birmingham [online]. Available from URL: Http://www.nmhdu.org.uk/national-events/nice-annualconference- 2011-birmingham-1011-may-2011/ [Accessed 2012 Jun 7]
17. Department of Health. A new value-based approach to the pricing of branded medicines: Government response to consultation. 2011 Jul 18 [online]. Available from URL: http://www.dh.gov.uk/en/Consultations/ Responsestoconsultations/DH-128226 [Accessed 2012 May 24]
18. Devlin N. EQ-5D: What it measures; what it misses; how it might evolve. Proceedings of the NICE Annual Conference. 2011 May 10-11; Birmingham [online]. Available from URL: ttp://www.nmhdu.org.uk/national-events/ nice-annual- conference-2011-birmingham-1011-may-2011/ [Accessed 2012 Jun 7]
19. Report by the NICE Decision Support Unit. The incorporation of health benefits in cost utility analysis using the EQ-5D. 2010 [online]. Available from URL: Http://www.nicedsu.org.uk/PDFs%20of%20reports/DSU%20EQ5D% 20final%20report%20-%20submitted.pdf [Accessed 2012 Jan 13]
20. Medicare Prescription Drug, Improvement, andModernization Act (MMA) of 2003, HR 1/Pub. L. No. 108-173, 117 Stat. 2066 (2003)
21. Sabharwal R, Giffin R, Rangarao S. What is comparative effectiveness research and what will it mean for patients, physicians, and payers? Baltimore (MD): Center for Medical Technology Policy, 2010
22. Patient Protection and Affordable Care Act, HR 3590 Pub. L. No. 111-148, 124 Stat. 119 (2010)
23. TheHealthCare and EducationReconciliationAct,HR4872/Pub. L. No. 111-152, 124 Stat. 1029 ( 2010)
24. American Recovery and Reinvestment Act, HR 1/Pub. L. No. 111-5, 123 Stat. 115 (2009)
25. U.S. Department of Health and Human Services. Federal Coordinating Council for Comparative Effectiveness Research: Report to the President and Congress, 2009 Jun 30
26. Chaplin S. NICE's future without a veto on the use of expensive drugs. Prescriber 2011; 22 (1-2): 18-25
27. Macmillan Cancer Support. Macmillan Cancer Support responds to the news that NICE will no longer have the power to ban drugs on the NHS. 1 November 2010 [online]. Available from URL: Http://www.macmillan.org.uk/ Aboutus/News/Latest- News/MacmillanCancerSupportrespondstothenewsthatNICEwillnolongerhavethepowertob andrugsontheNHS.aspx [Accessed 2012 Jan 16]
28. Roadmap for implementing value-driven health care in the traditional Medicare fee-for-service program. Centers for Medicare & Medicaid Services [online]. Available from URL: Https://www.cms.gov/QualityInitiativesGenInfo/ downloads/VBPRoadmap-OEA-1-16-508.pdf [Accessed 2011 Oct 15]
29. Stafford RS, Bartholomew LK, Cushman WC, et al., ALLHAT Collaborative Research Group. Impact of the ALLHAT/JNC7 Dissemination Project on thiazide-type diuretic use. Arch Int Med 2010; 170 (10): 851-8
30. Doyle J. The effect of comparative effectiveness research on drug development innovation: A 360- value appraisal. Comp Eff Res 2011; 1: 27-34
31. Neville S, Public Policy Editor. Review tackles cost of workplace illness. Financial Times; Nov 21 2011 [online]. Available from URL: Http://www.ft. com/cms/s/0/f4fc8428-1451-11e1-85c7-00144feabdc0.html [Accessed 2011 Nov 22]
32. Anell A. Priority setting for pharmaceuticals. Eur J Health Econ 2004; 5: 28-35